Pivotal Bioventure Partners Fund I G.p., L.p. - Net Worth and Insider Trading
Pivotal Bioventure Partners Fund I G.p., L.p. Net Worth
The estimated net worth of Pivotal Bioventure Partners Fund I G.p., L.p. is at least $33 Million dollars as of 2024-11-05. Pivotal Bioventure Partners Fund I G.p., L.p. is the 10% Owner of Akouos Inc and owns about 1,794,088 shares of Akouos Inc (AKUS) stock worth over $24 Million. Pivotal Bioventure Partners Fund I G.p., L.p. is the Director of Inozyme Pharma Inc and owns about 1,571,741 shares of Inozyme Pharma Inc (INZY) stock worth over $7 Million. Pivotal Bioventure Partners Fund I G.p., L.p. is also the 10% Owner of Entasis Therapeutics Holdings Inc and owns about 1,180,178 shares of Entasis Therapeutics Holdings Inc (ETTX) stock worth over $3 Million. Details can be seen in Pivotal Bioventure Partners Fund I G.p., L.p.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Pivotal Bioventure Partners Fund I G.p., L.p. has not made any transactions after 2023-08-01 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Pivotal Bioventure Partners Fund I G.p., L.p.
Pivotal Bioventure Partners Fund I G.p., L.p. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Pivotal Bioventure Partners Fund I G.p., L.p. owns 3 companies in total, including Inozyme Pharma Inc (INZY) , Akouos Inc (AKUS) , and Entasis Therapeutics Holdings Inc (ETTX) .
Insider Ownership Summary of Pivotal Bioventure Partners Fund I G.p., L.p.
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| INZY | Inozyme Pharma Inc | 2023-08-01 | director |
| AKUS | Akouos Inc | 2020-06-30 | 10 percent owner |
| ETTX | Entasis Therapeutics Holdings Inc | 2018-09-28 | 10 percent owner |
Pivotal Bioventure Partners Fund I G.p., L.p. Latest Holdings Summary
Pivotal Bioventure Partners Fund I G.p., L.p. currently owns a total of 3 stocks. Among these stocks, Pivotal Bioventure Partners Fund I G.p., L.p. owns 1,794,088 shares of Akouos Inc (AKUS) as of June 30, 2020, with a value of $24 Million and a weighting of 71.42%. Pivotal Bioventure Partners Fund I G.p., L.p. owns 1,571,741 shares of Inozyme Pharma Inc (INZY) as of August 1, 2023, with a value of $7 Million and a weighting of 20.83%. Pivotal Bioventure Partners Fund I G.p., L.p. also owns 1,180,178 shares of Entasis Therapeutics Holdings Inc (ETTX) as of September 28, 2018, with a value of $3 Million and a weighting of 7.74%.
Latest Holdings of Pivotal Bioventure Partners Fund I G.p., L.p.
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| AKUS | Akouos Inc | 2020-06-30 | 1,794,088 | 13.29 | 23,843,430 |
| INZY | Inozyme Pharma Inc | 2023-08-01 | 1,571,741 | 4.43 | 6,954,954 |
| ETTX | Entasis Therapeutics Holdings Inc | 2018-09-28 | 1,180,178 | 2.19 | 2,584,590 |
Holding Weightings of Pivotal Bioventure Partners Fund I G.p., L.p.
Pivotal Bioventure Partners Fund I G.p., L.p. Form 4 Trading Tracker
According to the SEC Form 4 filings, Pivotal Bioventure Partners Fund I G.p., L.p. has made a total of 1 transactions in Akouos Inc (AKUS) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Akouos Inc is the acquisition of 294,117 shares on June 30, 2020, which cost Pivotal Bioventure Partners Fund I G.p., L.p. around $5 Million.
According to the SEC Form 4 filings, Pivotal Bioventure Partners Fund I G.p., L.p. has made a total of 3 transactions in Inozyme Pharma Inc (INZY) over the past 5 years, including 3 buys and 0 sells. The most-recent trade in Inozyme Pharma Inc is the acquisition of 833,333 shares on August 1, 2023, which cost Pivotal Bioventure Partners Fund I G.p., L.p. around $4 Million.
According to the SEC Form 4 filings, Pivotal Bioventure Partners Fund I G.p., L.p. has made a total of 0 transactions in Entasis Therapeutics Holdings Inc (ETTX) over the past 5 years. The most-recent trade in Entasis Therapeutics Holdings Inc is the acquisition of 337,724 shares on September 28, 2018, which cost Pivotal Bioventure Partners Fund I G.p., L.p. around $5 Million.
Insider Trading History of Pivotal Bioventure Partners Fund I G.p., L.p.
- 1
Pivotal Bioventure Partners Fund I G.p., L.p. Trading Performance
GuruFocus tracks the stock performance after each of Pivotal Bioventure Partners Fund I G.p., L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Pivotal Bioventure Partners Fund I G.p., L.p. is -10.3%. GuruFocus also compares Pivotal Bioventure Partners Fund I G.p., L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Pivotal Bioventure Partners Fund I G.p., L.p. within 3 months outperforms 2 times out of 5 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Pivotal Bioventure Partners Fund I G.p., L.p.'s insider trading performs compared to the benchmark.
Performance of Pivotal Bioventure Partners Fund I G.p., L.p.
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -1.7 | | | | | |
| Relative Return to S&P 500(%) | 0.09 | | | | | |
Pivotal Bioventure Partners Fund I G.p., L.p. Ownership Network
Ownership Network List of Pivotal Bioventure Partners Fund I G.p., L.p.
Ownership Network Relation of Pivotal Bioventure Partners Fund I G.p., L.p.
Pivotal Bioventure Partners Fund I G.p., L.p. Owned Company Details
What does Inozyme Pharma Inc do?
Who are the key executives at Inozyme Pharma Inc?
Pivotal Bioventure Partners Fund I G.p., L.p. is the director of Inozyme Pharma Inc. Other key executives at Inozyme Pharma Inc include director & 10 percent owner Robert Lorne Hopfner , COO Matthew Winton , and See Remarks Henric Bjorn Bjarke .
Inozyme Pharma Inc (INZY) Insider Trades Summary
Over the past 18 months, Pivotal Bioventure Partners Fund I G.p., L.p. made 1 insider transaction in Inozyme Pharma Inc (INZY) with a net purchase of 833,333. Other recent insider transactions involving Inozyme Pharma Inc (INZY) include a net purchase of 1,281,265 shares made by Robert Lorne Hopfner , a net sale of 7,523 shares made by Douglas A Treco ,
In summary, during the past 3 months, insiders sold 0 shares of Inozyme Pharma Inc (INZY) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 7,523 shares of Inozyme Pharma Inc (INZY) were sold and 2,114,598 shares were bought by its insiders, resulting in a net purchase of 2,107,075 shares.
Inozyme Pharma Inc (INZY)'s detailed insider trading history can be found in Insider Trading Tracker table.
Inozyme Pharma Inc Insider Transactions
Pivotal Bioventure Partners Fund I G.p., L.p. Mailing Address
Above is the net worth, insider trading, and ownership report for Pivotal Bioventure Partners Fund I G.p., L.p.. You might contact Pivotal Bioventure Partners Fund I G.p., L.p. via mailing address: 501 Second Street, Suite 200, San Francisco Ca 94107.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
